Proton Bio logo — Empowering breakthroughs in Cell and Gene Therapy with compr...

Proton Bio

Empowering breakthroughs in Cell and Gene Therapy with comprehensive development and manufacturing solutions.

Founded 2018 201-500 employees Series B Total: $520.00M Biopharma, Biotechnology

General Information

Company Name Proton Bio
Founded Year 2018
Employees 201-500
Industries Biopharma, Biotechnology
Funding Stage Series B
Social

Get notified when Proton Bio moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Proton Bio

Proton Bio, a leader in Cell and Gene Therapy (CGT) solutions, is revolutionizing the biopharma and biotechnology industries with its comprehensive development and manufacturing services. Since its establishment in 2018, the company has been empowering breakthroughs in CGT, offering a range of services including process development, analytical development, GMP manufacturing, and testing at every stage from pre-clinical to commercialization. The recent CNY520.00M Series B investment on 19 August 2022 from an impressive lineup of investors including Hillhouse Investment, Huatai Health Fund, Huimei Capital, Advanced Manufacturing Industry Investment Fund, China Merchants Venture Capital, China Merchants Securities, Fosun Pharma, Huatai Zijin Investment further underscores Proton Bio's potential for growth and impact in the industry. With its mission to meet the evolving demands of the CGT sector, Proton Bio is poised for significant advancements and market influence.

Taxonomy: Cell Therapy, Gene Therapy, CDMO, Process Development, Analytical Development, GMP Manufacturing, Testing Services, Biopharmaceuticals, Therapeutic Products, Clinical Stage, Pre-clinical Stage, Commercial Stage, CDMO Services, Holistic Solutions, Comprehensive Services

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 8
Investor Investor
•••• ••••
19 Aug 2022

Proton Bio Alternatives & Competitors

Proton Bio vs

End-to-end ATMP CDMO/CRO that provides innovative offerings at each stage for biopharmaceutical prod...

Series B
46 employees
Biotechnology, Health and Wellness
Proton Bio vs

Trailblazing a path to global mental health through psilocybin therapy

Seed
8 employees
Biotechnology, Health and Wellness
Proton Bio vs

A clinical-stage company developing advanced antibody-drug conjugates.

FAQ About Proton Bio

Empowering breakthroughs in Cell and Gene Therapy with comprehensive development and manufacturing solutions.
Proton Bio was founded in 2018.
Proton Bio operates in the following industries: Biopharma, Biotechnology.
Proton Bio has approximately 201-500 employees.
Proton Bio has completed 1 funding round, raising a total of $520.00M. The latest funding stage is Series B.
Top alternatives and competitors to Proton Bio include Porton Advanced | ATMP CDMO/CRO, Clairvoyant Therapeutics, Oqory, Matica Biotechnology, Inc., Chime Biologics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Proton Bio and Porton Advanced | ATMP CDMO/CRO are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Proton Bio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy